# Hopewell Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hopewell-therapeutics

- Industry: Biotechnology
- Headquarters: Woburn, US
- Website: www.hopewell-tx.com
- Total disclosed funding: $25M
- Latest round: Seed (Jun 7, 2023)
- Investors on record: 6

## About

Based in Massachusetts, United States, and founded in 2018 by CEO Qiaobing Xu, Hopewell Therapeutics, Inc., a.k.a. Hopewell Therapeutics operates as a bio-tech company that utilizes differentiated lipid nanoparticle platform to harness unique ionizable lipid chemistry for to bring genomic medicines to patients. In May 2023, Hopewell Therapeutics raised USD 25 million in seed funding from 5Y Capital, Bopu Capital, Hike Capital, IMO Ventures, Mass Ave Capital and WS Investments.

The company provides novel genomic medicines by designing systemically administered LNPs (lipid nanoparticles) to specifically target extrahepatic tissues and cells throughout the body. Hopewell Therapeutics is also targeting diseases of the lung to develop its internal pipeline, as well as exploring the potential of its tissue-targeted lipid nanoparticles (ttLNPs) platform for patients with unmet needs in oncology, neurological disorders, rare genetic diseases, and infectious diseases.

The company plans to use its proceeds from May 2023 funding to advance the development of genomic medicines based on its differentiated ttLNP platform through both internal pipeline programs and external partnerships.

## Funding rounds

- Seed, Jun 7, 2023, $25M — 5Y Capital, WS Investments, Hike Capital, IMO Ventures, Mass Ave Capital, Bopu Capital

## Investors

- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Seed
- WS Investments (https://capitalatlas.ai/funds/ws-investments) — Seed
- Hike Capital (https://capitalatlas.ai/funds/hike-capital) — Seed
- IMO Ventures (https://capitalatlas.ai/funds/imo-ventures) — Seed
- Mass Ave Capital (https://capitalatlas.ai/funds/mass-ave-capital) — Seed
- Bopu Capital — Seed